Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (131-140 of 339) with videos related to

Pageof 34
Sort By:
European Journal of Haematology|October 26, 2011
Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjangeNorbert Gattermann, Andrea Jarisch, Rudolf Schlag, et al.
Haematologica|January 2, 2008
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosisAnnette H Schmitt-Graeff, Soon-Siong Teo, Manfred Olschewski, et al.
Cancers|December 23, 2022
Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic ComponentVictoria Platte, Anika Bergmann, Barbara Hildebrandt, et al.
American Journal of Hematology|October 5, 2020
Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemiaChristina Rautenberg, Ulrich Germing, Stefanie Stepanow, et al.
Transplantation|November 20, 2002
Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantationGuido Kobbe, Ulrich Germing, Manuel Aivado, et al.
Leukemia Research|December 22, 2009
Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromesAkira Matsuda, Ulrich Germing, Itsuro Jinnai, et al.
Cancers|February 24, 2024
Infectious Complications in Patients with Myelodysplastic Syndromes: A Report from the Düsseldorf MDS RegistryAnnika Kasprzak, Julia Andresen, Kathrin Nachtkamp, et al.
Future Oncology (London, England)|August 14, 2024
Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and EuropeMaria Diez-Campelo, Aylin Yucel, Ravi K Goyal, et al.
European Journal of Clinical Investigation|October 10, 2013
Proposed score for survival of patients with myelodysplastic syndromesWolfgang R Sperr, Michael Kundi, Friedrich Wimazal, et al.
Haematologica|June 23, 2022
A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndromeRami S Komrokji, Hetty E Carraway, Ulrich Germing, et al.
Pageof 34

Showing results (131-140 of 339) with videos related to

Sort By:
Pageof 34
European Journal of Haematology|October 26, 2011
Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjangeNorbert Gattermann, Andrea Jarisch, Rudolf Schlag, et al.
Haematologica|January 2, 2008
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosisAnnette H Schmitt-Graeff, Soon-Siong Teo, Manfred Olschewski, et al.
Cancers|December 23, 2022
Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic ComponentVictoria Platte, Anika Bergmann, Barbara Hildebrandt, et al.
American Journal of Hematology|October 5, 2020
Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemiaChristina Rautenberg, Ulrich Germing, Stefanie Stepanow, et al.
Transplantation|November 20, 2002
Treatment of secondary myelodysplastic syndrome after heart transplantation with chemotherapy and nonmyeloablative stem-cell transplantationGuido Kobbe, Ulrich Germing, Manuel Aivado, et al.
Leukemia Research|December 22, 2009
Differences in the distribution of subtypes according to the WHO classification 2008 between Japanese and German patients with refractory anemia according to the FAB classification in myelodysplastic syndromesAkira Matsuda, Ulrich Germing, Itsuro Jinnai, et al.
Cancers|February 24, 2024
Infectious Complications in Patients with Myelodysplastic Syndromes: A Report from the Düsseldorf MDS RegistryAnnika Kasprzak, Julia Andresen, Kathrin Nachtkamp, et al.
Future Oncology (London, England)|August 14, 2024
Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and EuropeMaria Diez-Campelo, Aylin Yucel, Ravi K Goyal, et al.
European Journal of Clinical Investigation|October 10, 2013
Proposed score for survival of patients with myelodysplastic syndromesWolfgang R Sperr, Michael Kundi, Friedrich Wimazal, et al.
Haematologica|June 23, 2022
A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndromeRami S Komrokji, Hetty E Carraway, Ulrich Germing, et al.
Pageof 34